Nektar surges again as alopecia drug shows new promise in extension study

Nektar Therapeutics said its experimental alopecia areata drug rezpegaldesleukin showed continued hair regrowth through 52 weeks, with 29% of low-dose and 31% of high-dose patients reaching SALT scores of 20 or below versus none of four placebo patients. The company is using the extended data to support late-stage development after an earlier 36-week readout missed statistical significance. Shares jumped nearly 25% in morning trading, reflecting improved confidence in the program.

Analysis

The market is likely pricing this as a binary clinical rescue story, but the more important signal is duration: the effect appears to strengthen with continued exposure, which shifts the commercial debate from “does it work?” to “how long until payers tolerate enough treatment time to see the benefit?” That matters because autoimmune dermatology is a persistence market; if the response curve keeps steepening beyond the first readout, the value of a differentiated chronic regimen rises materially versus shorter-course or less durable competitors.

For Nektar, the second-order upside is not just alopecia. A therapy that shows delayed deepening of response across two immune-mediated indications starts to look like a platform readthrough on mechanism, which can re-rate the asset class if validated in later-stage data. The key competitive implication is that the company may be able to position around durability and steroid-sparing behavior rather than pure speed of onset, which could support premium pricing if the responder pool is durable enough.

The risk is that the apparent improvement is coming from selection bias: the extension only follows early responders, so the 52-week data can overstate true population efficacy. If late-stage data fail to reproduce the same slope in an intention-to-treat design, the stock likely gives back a large chunk of the pop. The next 3-6 months are mostly a sentiment trade; the real fundamental inflection is 12-18 months away when randomized confirmatory data or partnering interest determines whether this is a real asset or a rescue narrative.

Contrarianly, the move may still be underpriced if investors focus too much on the prior miss and too little on mechanism + duration. In immunology, therapies that improve gradually often look mediocre at 24-36 weeks and compelling at 52+ weeks; if that pattern holds here, current valuation could still be modest relative to platform optionality. The flip side is that any disappointment in broader, non-responder cohorts would quickly expose how narrow the efficacy may be.

Key Decisions for Investors

• Long NKTR tactically for 2-6 weeks into follow-on catalyst risk; use strength to monetize part of the move, but keep a residual position for late-stage optionality. Risk/reward is attractive only while the market is re-pricing duration, not once the story becomes consensus.
• For more convex exposure, buy NKTR out-of-the-money calls 3-6 months out and finance with upside calls/spreads rather than outright stock. This captures another rerating leg if partnering or trial design improvements emerge, while capping premium at risk if the extension data fade.
• If carrying biotech relative-value risk, pair long NKTR against a basket short of higher-multiple, non-differentiated immunology names with less durable data. The thesis is that chronic autoimmune assets with visible response accumulation should outperform “one-and-done” programs over the next 1-2 quarters.
• Do not chase aggressively above the current move; set an entry only on a 10-15% retracement or on evidence of late-stage trial design clarity. The best risk/reward is on pullbacks because the stock is now trading more on narrative than on de-risked fundamentals.